Precision medicine refers to prevention and treatment strategies that take individual variability into account. St. Jude researchers are pioneering precision medicine for pediatric cancer patients, beginning with a focus on next-generation genome sequencing, cancer predisposition and pharmacogenomics.
Learn more about precision medicine and other drug discovery and therapeutic research at St. Jude.
The following precision medicine experts are available to speak to journalists on a range of topics related to precision medicine research and therapies.
To schedule interviews or speak with one of our experts, email firstname.lastname@example.org or contact one of our media relations staff.
Precision Medicine Experts
Charles Mullighan, MBBS (Hons), MSc, MD, is the St. Jude Comprehensive Cancer Center deputy director and the St. Jude Biorepository medical director. His research focuses on using integrated genomic, epigenomic and experimental approaches to understand acute lymphoblastic leukemia (ALL) and related disorders. He has led landmark studies that have defined the inherited and somatic genetic alterations in ALL. Mullighan can provide considerable insight into findings that have led to genomically informed diagnostic approaches and multiple clinical trials testing precision medicine approaches.
Mary Relling, PharmD, is the Pharmaceutical Sciences chair at St. Jude Children's Research Hospital. Recognized as one of the top-cited researchers by the Web of Science Group, Relling aims to improve drug therapy of childhood leukemia by understanding differences in a patient’s response to commonly used medications. Her lab uses a genome-wide approach to identify genetic variations that may affect the chance for cure and ones that may increase the risk of adverse effects of chemotherapy. Relling leads aclinical trial that integrates patient genome testing into St. Jude health records. The study aims to learn how to make medications more effective and safer in patients.